DNase I and Sivelestat Ameliorate Experimental Hindlimb Ischemia-Reperfusion Injury by Eliminating Neutrophil Extracellular Traps

Chun-Lian Wang,1 Yan Wang,2 Qi-Lan Jiang,3 Yang Zeng,4 Qing-Ping Yao,5 Xing Liu,6 Tao Li,7 Jun Jiang1 1Department of General Surgery (Thyroid Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China; 2Department of Cardiology, The Fourth Hospital of...

Full description

Saved in:
Bibliographic Details
Main Authors: Wang CL (Author), Wang Y (Author), Jiang QL (Author), Zeng Y (Author), Yao QP (Author), Liu X (Author), Li T (Author), Jiang J (Author)
Format: Book
Published: Dove Medical Press, 2023-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_61d7e8fd3a2c442d9ff78f76fe7aed0d
042 |a dc 
100 1 0 |a Wang CL  |e author 
700 1 0 |a Wang Y  |e author 
700 1 0 |a Jiang QL  |e author 
700 1 0 |a Zeng Y  |e author 
700 1 0 |a Yao QP  |e author 
700 1 0 |a Liu X  |e author 
700 1 0 |a Li T  |e author 
700 1 0 |a Jiang J  |e author 
245 0 0 |a DNase I and Sivelestat Ameliorate Experimental Hindlimb Ischemia-Reperfusion Injury by Eliminating Neutrophil Extracellular Traps 
260 |b Dove Medical Press,   |c 2023-02-01T00:00:00Z. 
500 |a 1178-7031 
520 |a Chun-Lian Wang,1 Yan Wang,2 Qi-Lan Jiang,3 Yang Zeng,4 Qing-Ping Yao,5 Xing Liu,6 Tao Li,7 Jun Jiang1 1Department of General Surgery (Thyroid Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China; 2Department of Cardiology, The Fourth Hospital of Harbin Medical University, Harbin, People's Republic of China; 3Department of Clinical Nutrition, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China; 4Department of Orthodontics, The Affiliated Stomatological Hospital of Southwest Medical University, Luzhou, People's Republic of China; 5Institute of Mechanobiology & Medical Engineering, School of Life Science & Biotechnology, Shanghai Jiao Tong University, Shanghai, People's Republic of China; 6Department of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China; 7Key Laboratory of Medical Electrophysiology of Ministry of Education, Collaborative Innovation Center for Prevention and Treatment of Cardiovascular Disease, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, People's Republic of ChinaCorrespondence: Jun Jiang; Tao Li, Email jiangjun@swmu.edu.cn; leta49@swmu.edu.cnPurpose: Neutrophil extracellular traps (NETs) play an important role in ischemia-reperfusion injury (IRI) of the hindlimb. The aim of this study was to investigate the effect of recombinant DNase I and sivelestat in eliminating NETs and their effects on IRI limbs.Patients and Methods: An air pump was used to apply a pressure of 300 mmHg to the root of the right hindlimb of the rat for 2 h and then deflated to replicate the IRI model. The formation of NETs was determined by the detection of myeloperoxidase (MPO), neutrophil elastase (NE), and histone H3 in the skeletal muscles of the hindlimbs. Animals were administered 2.5 mg/kg bw/d DNase I, 15 or 60 mg/kg bw/d sivelestat by injection into the tail vein or intramuscularly into the ischemic area for 7d. Elimination of NETs, hindlimb perfusion, muscle fibrosis, angiogenesis and motor function were assessed.Results: DNase I reduced NETs, attenuated muscle fibrosis, promoted angiogenesis in IRI area and improved limb motor function. Local administration of DNase I improved hindlimb perfusion more than intravenous administration. Sivelestat at a dose of 15 mg/kg bw/d increased perfusion, counteracted skeletal muscle fibrosis, promoted angiogenesis and enhanced motor function. However, sivelestat at a dosage of 60 mg/kg bw/d had an adverse effect on tissue repair, especially when injected locally.Conclusion: Both DNase I and moderate doses of sivelestat can eliminate IRI-derived NETs. They improve hindlimb function by improving perfusion and angiogenesis, preventing muscle fibrosis. Appropriate administration mode and dosage is the key to prevent IRI by elimination of NETs. DNase I is more valid when administered topically and sivelestat is more effective when administered intravenously. These results will provide a better strategy for the treatment of IRI in clinical.Keywords: ischemia-reperfusion injury, IRI, neutrophil extracellular traps, NETs, DNase I, sivelestat, hindlimb 
546 |a EN 
690 |a ischemia-reperfusion injury 
690 |a iri 
690 |a neutrophil extracellular traps 
690 |a nets 
690 |a dnase i 
690 |a sivelestat 
690 |a hindlimb 
690 |a Pathology 
690 |a RB1-214 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Journal of Inflammation Research, Vol Volume 16, Pp 707-721 (2023) 
787 0 |n https://www.dovepress.com/dnase-i-and-sivelestat-ameliorate-experimental-hindlimb-ischemia-reper-peer-reviewed-fulltext-article-JIR 
787 0 |n https://doaj.org/toc/1178-7031 
856 4 1 |u https://doaj.org/article/61d7e8fd3a2c442d9ff78f76fe7aed0d  |z Connect to this object online.